MEDICINA
Departamento
GlaxoSmithKline (Spain)
Madrid, EspañaPublicaciones en colaboración con investigadores/as de GlaxoSmithKline (Spain) (9)
2014
-
Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems
Health and Quality of Life Outcomes, Vol. 12, Núm. 1
2013
-
Coste económico directo del control y el tratamiento del lupus eritematoso sistémico activo y sus brotes en España: estudio LUCIE Direct cost of management and treatment of active systemic lupus erythematosus and its flares in Spain: the LUCIE Study
Revista Clinica Espanola, Vol. 213, Núm. 3, pp. 127-137
2010
-
Antimicrobial resistance among respiratory pathogens in Spain: Latest data and changes over 11 years (1996-1997 to 2006-2007)
Antimicrobial Agents and Chemotherapy, Vol. 54, Núm. 7, pp. 2953-2959
2008
-
Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens
HIV Clinical Trials, Vol. 9, Núm. 5, pp. 309-313
2004
-
Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients
HIV Clinical Trials, Vol. 5, Núm. 1, pp. 33-39
2003
-
Comités éticos de investigación clínica y «dictamen único» de los ensayos clínicos multicéntricos
Medicina Clinica, Vol. 120, Núm. 5, pp. 180-188
2002
-
Activities of six different quinolones against clinical respiratory isolates of streptococcus pneumoniae with reduced susceptibility to ciprofloxacin in Spain
Antimicrobial Agents and Chemotherapy, Vol. 46, Núm. 8, pp. 2665-2667
-
Activity of six quinolones against 226 recent clinical isolates of Streptococcus pyogenes with reduced susceptibility to ciprofloxacin [3]
Journal of Antimicrobial Chemotherapy
2001
-
Antimicrobial susceptibilities of 1,730 Haemophilus influenzae respiratory tract isolates in Spain in 1998-1999
Antimicrobial Agents and Chemotherapy, Vol. 45, Núm. 11, pp. 3226-3228